Global Imbruvica
Global Imbruvica

Imbruvica Comprehensive Study by Type (70 mg Capsule, 140 mg Capsule), Application (Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenström's Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma, Chronic Graft-Versus-Host-Disease), Drug Form (Tablet, Capsule), Tablets (140mg, 280mg, 420mg, 560mg), Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies) Players and Region - Global Market Outlook to 2025

Imbruvica Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 217 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Imbruvica Market Overview:
Imbruvica is an inhibitor of Bruton’s tyrosine kinase. Imbruvica is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy; for the treatment of chronic lymphocytic leukemia /small lymphocytic lymphoma; for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion; and for chronic graft versus host disease (cGVHD) after the failure of one or more lines of system therapy.

Growth Drivers
  • Increasing Prevalence of Cancer Diseases Across the World
  • Rising Number of Patients with Lymphomas and Leukemia

Market Trends
  • Rising Clinical Trial

Roadblocks
  • Side Effect Imbruvica such as Upset Stomach, Diarrhea, Nausea, Vomiting, Decreased Appetite, etc.

Opportunities
  • Rising Healthcare Sector Across the World
  • Growing Cancer Treatment with Specified Treatment Drugs

Challenges
  • Stringent Regulatory Process


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new drug launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies
Some of the key players profiled in the report are AbbVie Inc.(Pharmacyclics) (United States), Johnson & Johnson (Janssen Biotech) (United States), SP Laboratories (Serbia), Beacon Pharmaceuticals (Bangladesh), Incepta Pharmaceuticals (Bangladesh) and Bluepharma (Portugal). Considering Market by Drug Form, the sub-segment i.e. Tablet will boost the Imbruvica market. Considering Market by Tablets, the sub-segment i.e. 140mg will boost the Imbruvica market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Imbruvica market.

In April 2020, The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy., and In Dec 2019, Hyderabad-based Natco Pharma NSE -0.34 % has launched a cut-price version of ibrutinib, an anti-cancer drug, under its own brand name Ibrunat. The patent for the drug is held by Pharmacyclics for three to four more years in India.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Imbruvica market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Imbruvica market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Imbruvica Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • 70 mg Capsule
  • 140 mg Capsule
By Application
  • Mantle Cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Waldenström's Macroglobulinemia
  • Relapsed/Refractory Marginal Zone Lymphoma
  • Chronic Graft-Versus-Host-Disease
By Drug Form
  • Tablet
  • Capsule

By Tablets
  • 140mg
  • 280mg
  • 420mg
  • 560mg

By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cancer Diseases Across the World
      • 3.2.2. Rising Number of Patients with Lymphomas and Leukemia
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Process
    • 3.4. Market Trends
      • 3.4.1. Rising Clinical Trial
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Imbruvica, by Type, Application, Drug Form, Tablets, Distribution Channel and Region (value and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Imbruvica (Value)
      • 5.2.1. Global Imbruvica by: Type (Value)
        • 5.2.1.1. 70 mg Capsule
        • 5.2.1.2. 140 mg Capsule
      • 5.2.2. Global Imbruvica by: Application (Value)
        • 5.2.2.1. Mantle Cell Lymphoma
        • 5.2.2.2. Chronic Lymphocytic Leukemia
        • 5.2.2.3. Waldenström's Macroglobulinemia
        • 5.2.2.4. Relapsed/Refractory Marginal Zone Lymphoma
        • 5.2.2.5. Chronic Graft-Versus-Host-Disease
      • 5.2.3. Global Imbruvica by: Drug Form (Value)
        • 5.2.3.1. Tablet
        • 5.2.3.2. Capsule
      • 5.2.4. Global Imbruvica by: Tablets (Value)
        • 5.2.4.1. 140mg
        • 5.2.4.2. 280mg
        • 5.2.4.3. 420mg
        • 5.2.4.4. 560mg
      • 5.2.5. Global Imbruvica by: Distribution Channel (Value)
        • 5.2.5.1. Hospital Pharmacies
        • 5.2.5.2. Drug Stores
        • 5.2.5.3. Retail Pharmacies
      • 5.2.6. Global Imbruvica Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Imbruvica (Price)
      • 5.3.1. Global Imbruvica by: Type (Price)
  • 6. Imbruvica: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie Inc.(Pharmacyclics) (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (Janssen Biotech) (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. SP Laboratories (Serbia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Beacon Pharmaceuticals (Bangladesh)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Incepta Pharmaceuticals (Bangladesh)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bluepharma (Portugal)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Global Imbruvica Sale, by Type, Application, Drug Form, Tablets, Distribution Channel and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Imbruvica (Value)
      • 7.2.1. Global Imbruvica by: Type (Value)
        • 7.2.1.1. 70 mg Capsule
        • 7.2.1.2. 140 mg Capsule
      • 7.2.2. Global Imbruvica by: Application (Value)
        • 7.2.2.1. Mantle Cell Lymphoma
        • 7.2.2.2. Chronic Lymphocytic Leukemia
        • 7.2.2.3. Waldenström's Macroglobulinemia
        • 7.2.2.4. Relapsed/Refractory Marginal Zone Lymphoma
        • 7.2.2.5. Chronic Graft-Versus-Host-Disease
      • 7.2.3. Global Imbruvica by: Drug Form (Value)
        • 7.2.3.1. Tablet
        • 7.2.3.2. Capsule
      • 7.2.4. Global Imbruvica by: Tablets (Value)
        • 7.2.4.1. 140mg
        • 7.2.4.2. 280mg
        • 7.2.4.3. 420mg
        • 7.2.4.4. 560mg
      • 7.2.5. Global Imbruvica by: Distribution Channel (Value)
        • 7.2.5.1. Hospital Pharmacies
        • 7.2.5.2. Drug Stores
        • 7.2.5.3. Retail Pharmacies
      • 7.2.6. Global Imbruvica Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Imbruvica (Price)
      • 7.3.1. Global Imbruvica by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Imbruvica: by Type(USD Million)
  • Table 2. Imbruvica 70 mg Capsule , by Region USD Million (2014-2019)
  • Table 3. Imbruvica 140 mg Capsule , by Region USD Million (2014-2019)
  • Table 4. Imbruvica: by Application(USD Million)
  • Table 5. Imbruvica Mantle Cell Lymphoma , by Region USD Million (2014-2019)
  • Table 6. Imbruvica Chronic Lymphocytic Leukemia , by Region USD Million (2014-2019)
  • Table 7. Imbruvica Waldenström's Macroglobulinemia , by Region USD Million (2014-2019)
  • Table 8. Imbruvica Relapsed/Refractory Marginal Zone Lymphoma , by Region USD Million (2014-2019)
  • Table 9. Imbruvica Chronic Graft-Versus-Host-Disease , by Region USD Million (2014-2019)
  • Table 10. Imbruvica: by Drug Form(USD Million)
  • Table 11. Imbruvica Tablet , by Region USD Million (2014-2019)
  • Table 12. Imbruvica Capsule , by Region USD Million (2014-2019)
  • Table 13. Imbruvica: by Tablets(USD Million)
  • Figure 7. Global Imbruvica: by Tablets USD Million (2014-2019)
  • Table 14. Imbruvica 140mg , by Region USD Million (2014-2019)
  • Table 15. Imbruvica 280mg , by Region USD Million (2014-2019)
  • Table 16. Imbruvica 420mg , by Region USD Million (2014-2019)
  • Table 17. Imbruvica 560mg , by Region USD Million (2014-2019)
  • Table 18. Imbruvica: by Distribution Channel(USD Million)
  • Table 19. Imbruvica Hospital Pharmacies , by Region USD Million (2014-2019)
  • Table 20. Imbruvica Drug Stores , by Region USD Million (2014-2019)
  • Table 21. Imbruvica Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 22. South America Imbruvica, by Country USD Million (2014-2019)
  • Table 23. South America Imbruvica, by Type USD Million (2014-2019)
  • Table 24. South America Imbruvica, by Application USD Million (2014-2019)
  • Table 25. South America Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 26. South America Imbruvica, by Tablets USD Million (2014-2019)
  • Table 27. South America Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 28. Brazil Imbruvica, by Type USD Million (2014-2019)
  • Table 29. Brazil Imbruvica, by Application USD Million (2014-2019)
  • Table 30. Brazil Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 31. Brazil Imbruvica, by Tablets USD Million (2014-2019)
  • Table 32. Brazil Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 33. Argentina Imbruvica, by Type USD Million (2014-2019)
  • Table 34. Argentina Imbruvica, by Application USD Million (2014-2019)
  • Table 35. Argentina Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 36. Argentina Imbruvica, by Tablets USD Million (2014-2019)
  • Table 37. Argentina Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 38. Rest of South America Imbruvica, by Type USD Million (2014-2019)
  • Table 39. Rest of South America Imbruvica, by Application USD Million (2014-2019)
  • Table 40. Rest of South America Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 41. Rest of South America Imbruvica, by Tablets USD Million (2014-2019)
  • Table 42. Rest of South America Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 43. Asia Pacific Imbruvica, by Country USD Million (2014-2019)
  • Table 44. Asia Pacific Imbruvica, by Type USD Million (2014-2019)
  • Table 45. Asia Pacific Imbruvica, by Application USD Million (2014-2019)
  • Table 46. Asia Pacific Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 47. Asia Pacific Imbruvica, by Tablets USD Million (2014-2019)
  • Table 48. Asia Pacific Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 49. China Imbruvica, by Type USD Million (2014-2019)
  • Table 50. China Imbruvica, by Application USD Million (2014-2019)
  • Table 51. China Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 52. China Imbruvica, by Tablets USD Million (2014-2019)
  • Table 53. China Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 54. Japan Imbruvica, by Type USD Million (2014-2019)
  • Table 55. Japan Imbruvica, by Application USD Million (2014-2019)
  • Table 56. Japan Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 57. Japan Imbruvica, by Tablets USD Million (2014-2019)
  • Table 58. Japan Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 59. India Imbruvica, by Type USD Million (2014-2019)
  • Table 60. India Imbruvica, by Application USD Million (2014-2019)
  • Table 61. India Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 62. India Imbruvica, by Tablets USD Million (2014-2019)
  • Table 63. India Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 64. South Korea Imbruvica, by Type USD Million (2014-2019)
  • Table 65. South Korea Imbruvica, by Application USD Million (2014-2019)
  • Table 66. South Korea Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 67. South Korea Imbruvica, by Tablets USD Million (2014-2019)
  • Table 68. South Korea Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 69. Taiwan Imbruvica, by Type USD Million (2014-2019)
  • Table 70. Taiwan Imbruvica, by Application USD Million (2014-2019)
  • Table 71. Taiwan Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 72. Taiwan Imbruvica, by Tablets USD Million (2014-2019)
  • Table 73. Taiwan Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 74. Australia Imbruvica, by Type USD Million (2014-2019)
  • Table 75. Australia Imbruvica, by Application USD Million (2014-2019)
  • Table 76. Australia Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 77. Australia Imbruvica, by Tablets USD Million (2014-2019)
  • Table 78. Australia Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 79. Rest of Asia-Pacific Imbruvica, by Type USD Million (2014-2019)
  • Table 80. Rest of Asia-Pacific Imbruvica, by Application USD Million (2014-2019)
  • Table 81. Rest of Asia-Pacific Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 82. Rest of Asia-Pacific Imbruvica, by Tablets USD Million (2014-2019)
  • Table 83. Rest of Asia-Pacific Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 84. Europe Imbruvica, by Country USD Million (2014-2019)
  • Table 85. Europe Imbruvica, by Type USD Million (2014-2019)
  • Table 86. Europe Imbruvica, by Application USD Million (2014-2019)
  • Table 87. Europe Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 88. Europe Imbruvica, by Tablets USD Million (2014-2019)
  • Table 89. Europe Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 90. Germany Imbruvica, by Type USD Million (2014-2019)
  • Table 91. Germany Imbruvica, by Application USD Million (2014-2019)
  • Table 92. Germany Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 93. Germany Imbruvica, by Tablets USD Million (2014-2019)
  • Table 94. Germany Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 95. France Imbruvica, by Type USD Million (2014-2019)
  • Table 96. France Imbruvica, by Application USD Million (2014-2019)
  • Table 97. France Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 98. France Imbruvica, by Tablets USD Million (2014-2019)
  • Table 99. France Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 100. Italy Imbruvica, by Type USD Million (2014-2019)
  • Table 101. Italy Imbruvica, by Application USD Million (2014-2019)
  • Table 102. Italy Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 103. Italy Imbruvica, by Tablets USD Million (2014-2019)
  • Table 104. Italy Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 105. United Kingdom Imbruvica, by Type USD Million (2014-2019)
  • Table 106. United Kingdom Imbruvica, by Application USD Million (2014-2019)
  • Table 107. United Kingdom Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 108. United Kingdom Imbruvica, by Tablets USD Million (2014-2019)
  • Table 109. United Kingdom Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 110. Netherlands Imbruvica, by Type USD Million (2014-2019)
  • Table 111. Netherlands Imbruvica, by Application USD Million (2014-2019)
  • Table 112. Netherlands Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 113. Netherlands Imbruvica, by Tablets USD Million (2014-2019)
  • Table 114. Netherlands Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 115. Rest of Europe Imbruvica, by Type USD Million (2014-2019)
  • Table 116. Rest of Europe Imbruvica, by Application USD Million (2014-2019)
  • Table 117. Rest of Europe Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 118. Rest of Europe Imbruvica, by Tablets USD Million (2014-2019)
  • Table 119. Rest of Europe Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 120. MEA Imbruvica, by Country USD Million (2014-2019)
  • Table 121. MEA Imbruvica, by Type USD Million (2014-2019)
  • Table 122. MEA Imbruvica, by Application USD Million (2014-2019)
  • Table 123. MEA Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 124. MEA Imbruvica, by Tablets USD Million (2014-2019)
  • Table 125. MEA Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 126. Middle East Imbruvica, by Type USD Million (2014-2019)
  • Table 127. Middle East Imbruvica, by Application USD Million (2014-2019)
  • Table 128. Middle East Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 129. Middle East Imbruvica, by Tablets USD Million (2014-2019)
  • Table 130. Middle East Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 131. Africa Imbruvica, by Type USD Million (2014-2019)
  • Table 132. Africa Imbruvica, by Application USD Million (2014-2019)
  • Table 133. Africa Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 134. Africa Imbruvica, by Tablets USD Million (2014-2019)
  • Table 135. Africa Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 136. North America Imbruvica, by Country USD Million (2014-2019)
  • Table 137. North America Imbruvica, by Type USD Million (2014-2019)
  • Table 138. North America Imbruvica, by Application USD Million (2014-2019)
  • Table 139. North America Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 140. North America Imbruvica, by Tablets USD Million (2014-2019)
  • Table 141. North America Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 142. United States Imbruvica, by Type USD Million (2014-2019)
  • Table 143. United States Imbruvica, by Application USD Million (2014-2019)
  • Table 144. United States Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 145. United States Imbruvica, by Tablets USD Million (2014-2019)
  • Table 146. United States Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 147. Canada Imbruvica, by Type USD Million (2014-2019)
  • Table 148. Canada Imbruvica, by Application USD Million (2014-2019)
  • Table 149. Canada Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 150. Canada Imbruvica, by Tablets USD Million (2014-2019)
  • Table 151. Canada Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 152. Mexico Imbruvica, by Type USD Million (2014-2019)
  • Table 153. Mexico Imbruvica, by Application USD Million (2014-2019)
  • Table 154. Mexico Imbruvica, by Drug Form USD Million (2014-2019)
  • Table 155. Mexico Imbruvica, by Tablets USD Million (2014-2019)
  • Table 156. Mexico Imbruvica, by Distribution Channel USD Million (2014-2019)
  • Table 157. Imbruvica: by Type(USD/Units)
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Imbruvica: by Type(USD Million)
  • Table 165. Imbruvica 70 mg Capsule , by Region USD Million (2020-2025)
  • Table 166. Imbruvica 140 mg Capsule , by Region USD Million (2020-2025)
  • Table 167. Imbruvica: by Application(USD Million)
  • Table 168. Imbruvica Mantle Cell Lymphoma , by Region USD Million (2020-2025)
  • Table 169. Imbruvica Chronic Lymphocytic Leukemia , by Region USD Million (2020-2025)
  • Table 170. Imbruvica Waldenström's Macroglobulinemia , by Region USD Million (2020-2025)
  • Table 171. Imbruvica Relapsed/Refractory Marginal Zone Lymphoma , by Region USD Million (2020-2025)
  • Table 172. Imbruvica Chronic Graft-Versus-Host-Disease , by Region USD Million (2020-2025)
  • Table 173. Imbruvica: by Drug Form(USD Million)
  • Table 174. Imbruvica Tablet , by Region USD Million (2020-2025)
  • Table 175. Imbruvica Capsule , by Region USD Million (2020-2025)
  • Table 176. Imbruvica: by Tablets(USD Million)
  • Figure 33. Global Imbruvica: by Tablets USD Million (2020-2025)
  • Table 177. Imbruvica 140mg , by Region USD Million (2020-2025)
  • Table 178. Imbruvica 280mg , by Region USD Million (2020-2025)
  • Table 179. Imbruvica 420mg , by Region USD Million (2020-2025)
  • Table 180. Imbruvica 560mg , by Region USD Million (2020-2025)
  • Table 181. Imbruvica: by Distribution Channel(USD Million)
  • Table 182. Imbruvica Hospital Pharmacies , by Region USD Million (2020-2025)
  • Table 183. Imbruvica Drug Stores , by Region USD Million (2020-2025)
  • Table 184. Imbruvica Retail Pharmacies , by Region USD Million (2020-2025)
  • Table 185. South America Imbruvica, by Country USD Million (2020-2025)
  • Table 186. South America Imbruvica, by Type USD Million (2020-2025)
  • Table 187. South America Imbruvica, by Application USD Million (2020-2025)
  • Table 188. South America Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 189. South America Imbruvica, by Tablets USD Million (2020-2025)
  • Table 190. South America Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 191. Brazil Imbruvica, by Type USD Million (2020-2025)
  • Table 192. Brazil Imbruvica, by Application USD Million (2020-2025)
  • Table 193. Brazil Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 194. Brazil Imbruvica, by Tablets USD Million (2020-2025)
  • Table 195. Brazil Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 196. Argentina Imbruvica, by Type USD Million (2020-2025)
  • Table 197. Argentina Imbruvica, by Application USD Million (2020-2025)
  • Table 198. Argentina Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 199. Argentina Imbruvica, by Tablets USD Million (2020-2025)
  • Table 200. Argentina Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 201. Rest of South America Imbruvica, by Type USD Million (2020-2025)
  • Table 202. Rest of South America Imbruvica, by Application USD Million (2020-2025)
  • Table 203. Rest of South America Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 204. Rest of South America Imbruvica, by Tablets USD Million (2020-2025)
  • Table 205. Rest of South America Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 206. Asia Pacific Imbruvica, by Country USD Million (2020-2025)
  • Table 207. Asia Pacific Imbruvica, by Type USD Million (2020-2025)
  • Table 208. Asia Pacific Imbruvica, by Application USD Million (2020-2025)
  • Table 209. Asia Pacific Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 210. Asia Pacific Imbruvica, by Tablets USD Million (2020-2025)
  • Table 211. Asia Pacific Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 212. China Imbruvica, by Type USD Million (2020-2025)
  • Table 213. China Imbruvica, by Application USD Million (2020-2025)
  • Table 214. China Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 215. China Imbruvica, by Tablets USD Million (2020-2025)
  • Table 216. China Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 217. Japan Imbruvica, by Type USD Million (2020-2025)
  • Table 218. Japan Imbruvica, by Application USD Million (2020-2025)
  • Table 219. Japan Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 220. Japan Imbruvica, by Tablets USD Million (2020-2025)
  • Table 221. Japan Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 222. India Imbruvica, by Type USD Million (2020-2025)
  • Table 223. India Imbruvica, by Application USD Million (2020-2025)
  • Table 224. India Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 225. India Imbruvica, by Tablets USD Million (2020-2025)
  • Table 226. India Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 227. South Korea Imbruvica, by Type USD Million (2020-2025)
  • Table 228. South Korea Imbruvica, by Application USD Million (2020-2025)
  • Table 229. South Korea Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 230. South Korea Imbruvica, by Tablets USD Million (2020-2025)
  • Table 231. South Korea Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 232. Taiwan Imbruvica, by Type USD Million (2020-2025)
  • Table 233. Taiwan Imbruvica, by Application USD Million (2020-2025)
  • Table 234. Taiwan Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 235. Taiwan Imbruvica, by Tablets USD Million (2020-2025)
  • Table 236. Taiwan Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 237. Australia Imbruvica, by Type USD Million (2020-2025)
  • Table 238. Australia Imbruvica, by Application USD Million (2020-2025)
  • Table 239. Australia Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 240. Australia Imbruvica, by Tablets USD Million (2020-2025)
  • Table 241. Australia Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 242. Rest of Asia-Pacific Imbruvica, by Type USD Million (2020-2025)
  • Table 243. Rest of Asia-Pacific Imbruvica, by Application USD Million (2020-2025)
  • Table 244. Rest of Asia-Pacific Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 245. Rest of Asia-Pacific Imbruvica, by Tablets USD Million (2020-2025)
  • Table 246. Rest of Asia-Pacific Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 247. Europe Imbruvica, by Country USD Million (2020-2025)
  • Table 248. Europe Imbruvica, by Type USD Million (2020-2025)
  • Table 249. Europe Imbruvica, by Application USD Million (2020-2025)
  • Table 250. Europe Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 251. Europe Imbruvica, by Tablets USD Million (2020-2025)
  • Table 252. Europe Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 253. Germany Imbruvica, by Type USD Million (2020-2025)
  • Table 254. Germany Imbruvica, by Application USD Million (2020-2025)
  • Table 255. Germany Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 256. Germany Imbruvica, by Tablets USD Million (2020-2025)
  • Table 257. Germany Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 258. France Imbruvica, by Type USD Million (2020-2025)
  • Table 259. France Imbruvica, by Application USD Million (2020-2025)
  • Table 260. France Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 261. France Imbruvica, by Tablets USD Million (2020-2025)
  • Table 262. France Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 263. Italy Imbruvica, by Type USD Million (2020-2025)
  • Table 264. Italy Imbruvica, by Application USD Million (2020-2025)
  • Table 265. Italy Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 266. Italy Imbruvica, by Tablets USD Million (2020-2025)
  • Table 267. Italy Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 268. United Kingdom Imbruvica, by Type USD Million (2020-2025)
  • Table 269. United Kingdom Imbruvica, by Application USD Million (2020-2025)
  • Table 270. United Kingdom Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 271. United Kingdom Imbruvica, by Tablets USD Million (2020-2025)
  • Table 272. United Kingdom Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 273. Netherlands Imbruvica, by Type USD Million (2020-2025)
  • Table 274. Netherlands Imbruvica, by Application USD Million (2020-2025)
  • Table 275. Netherlands Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 276. Netherlands Imbruvica, by Tablets USD Million (2020-2025)
  • Table 277. Netherlands Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 278. Rest of Europe Imbruvica, by Type USD Million (2020-2025)
  • Table 279. Rest of Europe Imbruvica, by Application USD Million (2020-2025)
  • Table 280. Rest of Europe Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 281. Rest of Europe Imbruvica, by Tablets USD Million (2020-2025)
  • Table 282. Rest of Europe Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 283. MEA Imbruvica, by Country USD Million (2020-2025)
  • Table 284. MEA Imbruvica, by Type USD Million (2020-2025)
  • Table 285. MEA Imbruvica, by Application USD Million (2020-2025)
  • Table 286. MEA Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 287. MEA Imbruvica, by Tablets USD Million (2020-2025)
  • Table 288. MEA Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 289. Middle East Imbruvica, by Type USD Million (2020-2025)
  • Table 290. Middle East Imbruvica, by Application USD Million (2020-2025)
  • Table 291. Middle East Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 292. Middle East Imbruvica, by Tablets USD Million (2020-2025)
  • Table 293. Middle East Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 294. Africa Imbruvica, by Type USD Million (2020-2025)
  • Table 295. Africa Imbruvica, by Application USD Million (2020-2025)
  • Table 296. Africa Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 297. Africa Imbruvica, by Tablets USD Million (2020-2025)
  • Table 298. Africa Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 299. North America Imbruvica, by Country USD Million (2020-2025)
  • Table 300. North America Imbruvica, by Type USD Million (2020-2025)
  • Table 301. North America Imbruvica, by Application USD Million (2020-2025)
  • Table 302. North America Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 303. North America Imbruvica, by Tablets USD Million (2020-2025)
  • Table 304. North America Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 305. United States Imbruvica, by Type USD Million (2020-2025)
  • Table 306. United States Imbruvica, by Application USD Million (2020-2025)
  • Table 307. United States Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 308. United States Imbruvica, by Tablets USD Million (2020-2025)
  • Table 309. United States Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 310. Canada Imbruvica, by Type USD Million (2020-2025)
  • Table 311. Canada Imbruvica, by Application USD Million (2020-2025)
  • Table 312. Canada Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 313. Canada Imbruvica, by Tablets USD Million (2020-2025)
  • Table 314. Canada Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 315. Mexico Imbruvica, by Type USD Million (2020-2025)
  • Table 316. Mexico Imbruvica, by Application USD Million (2020-2025)
  • Table 317. Mexico Imbruvica, by Drug Form USD Million (2020-2025)
  • Table 318. Mexico Imbruvica, by Tablets USD Million (2020-2025)
  • Table 319. Mexico Imbruvica, by Distribution Channel USD Million (2020-2025)
  • Table 320. Imbruvica: by Type(USD/Units)
  • Table 321. Research Programs/Design for This Report
  • Table 322. Key Data Information from Secondary Sources
  • Table 323. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Imbruvica: by Type USD Million (2014-2019)
  • Figure 5. Global Imbruvica: by Application USD Million (2014-2019)
  • Figure 6. Global Imbruvica: by Drug Form USD Million (2014-2019)
  • Figure 8. Global Imbruvica: by Distribution Channel USD Million (2014-2019)
  • Figure 9. South America Imbruvica Share (%), by Country
  • Figure 10. Asia Pacific Imbruvica Share (%), by Country
  • Figure 11. Europe Imbruvica Share (%), by Country
  • Figure 12. MEA Imbruvica Share (%), by Country
  • Figure 13. North America Imbruvica Share (%), by Country
  • Figure 14. Global Imbruvica: by Type USD/Units (2014-2019)
  • Figure 15. Global Imbruvica share by Players 2019 (%)
  • Figure 16. Global Imbruvica share by Players (Top 3) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. AbbVie Inc.(Pharmacyclics) (United States) Revenue, Net Income and Gross profit
  • Figure 19. AbbVie Inc.(Pharmacyclics) (United States) Revenue: by Geography 2019
  • Figure 20. Johnson & Johnson (Janssen Biotech) (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson & Johnson (Janssen Biotech) (United States) Revenue: by Geography 2019
  • Figure 22. SP Laboratories (Serbia) Revenue, Net Income and Gross profit
  • Figure 23. SP Laboratories (Serbia) Revenue: by Geography 2019
  • Figure 24. Beacon Pharmaceuticals (Bangladesh) Revenue, Net Income and Gross profit
  • Figure 25. Beacon Pharmaceuticals (Bangladesh) Revenue: by Geography 2019
  • Figure 26. Incepta Pharmaceuticals (Bangladesh) Revenue, Net Income and Gross profit
  • Figure 27. Incepta Pharmaceuticals (Bangladesh) Revenue: by Geography 2019
  • Figure 28. Bluepharma (Portugal) Revenue, Net Income and Gross profit
  • Figure 29. Bluepharma (Portugal) Revenue: by Geography 2019
  • Figure 30. Global Imbruvica: by Type USD Million (2020-2025)
  • Figure 31. Global Imbruvica: by Application USD Million (2020-2025)
  • Figure 32. Global Imbruvica: by Drug Form USD Million (2020-2025)
  • Figure 34. Global Imbruvica: by Distribution Channel USD Million (2020-2025)
  • Figure 35. South America Imbruvica Share (%), by Country
  • Figure 36. Asia Pacific Imbruvica Share (%), by Country
  • Figure 37. Europe Imbruvica Share (%), by Country
  • Figure 38. MEA Imbruvica Share (%), by Country
  • Figure 39. North America Imbruvica Share (%), by Country
  • Figure 40. Global Imbruvica: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • AbbVie Inc.(Pharmacyclics) (United States)
  • Johnson & Johnson (Janssen Biotech) (United States)
  • SP Laboratories (Serbia)
  • Beacon Pharmaceuticals (Bangladesh)
  • Incepta Pharmaceuticals (Bangladesh)
  • Bluepharma (Portugal)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation